About Me

I am a T32 Post-Doctoral Research Fellow at Harvard Medical School and Massachusetts General Hospital in the Center for Immunology and Inflammatory Diseases. Under the mentorship of Robert M. Anthony and Michelle E. Conroy, my research explores the role and regulation of antibody glycosylation in health and disease. My work in the Anthony lab aims to develop strategies that target and modulate glycosylation to produce therapeutics to treat immunological diseases, such as cancer.

Beyond my research, I serve as a Scientific Advisor and Contributor for Technology Networks, where I apply my expertise in immunology, bioprocessing, and biochemical engineering to translate complex scientific advances for a broader audience. I also advise and consult for biotech and pharmaceutical companies on research and development initiatives. In addition, I serve as Associate Director of the Harvard Mini MBA Program, helping integrate business strategy into biomedical and academic innovation.

I received my PhD in Biochemical Engineering from the Department of Chemical Engineering at Rutgers University. My doctoral research focused on engineering a system to study and control N-linked glycosylation of monoclonal antibodies for the biomanufacture of immunotherapies. This innovative system, which I developed, was subsequently patented under the name “N-Glycanyzer”. I served as an ORISE Fellow at the Food and Drug Administration’s Center for Drug Evaluation and Research (FDA-CDER), where I validated the N-Glycanyzer system, demonstrating its practical applications in a regulatory environment.